Accepted for/Published in: JMIR Medical Informatics
Date Submitted: Feb 24, 2020
Open Peer Review Period: Feb 24, 2020 - Apr 20, 2020
Date Accepted: Jun 15, 2020
(closed for review but you can still tweet)
Fueling Dementia Research in Appalachia via Appalachian Informatics Platform: Initial Findings from a Longitudinal Study on Benzodiazepine Prescription Patterns in a Geriatric Population
ABSTRACT
Background:
Caring for the growing dementia patient population with complex healthcare needs in West Virginia has been challenging due to its large, sizably rural-dwelling geriatric population and limited resource availability.
Objective:
To illustrate the application of an informatics platform to drive dementia research and quality care through a preliminary study of benzodiazepine (BZD) prescription patterns and its effects on healthcare utilization by geriatric patients.
Methods:
The Maier Institute Data Mart containing clinical and billing data on patients aged ≥ 65 (n=98,970) seen within our clinics/hospital was created. Relevant variables were analyzed to identify BZD prescription patterns and calculate related charges and emergency department (ED) utilization.
Results:
Nearly one third dementia patients received ≥ 1 BZD prescription, 20% more than those without dementia. More women than men received at least one BZD prescription. On average, patients with dementia and ≥ 1 BZD prescription sustained higher charges and visited the ED more often than those without one.
Conclusions:
The Appalachian informatics platform has the potential to enhance dementia care/research through a deeper understanding of dementia, data enrichment, risk identification, and care gap analysis.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.